ArcticZymes Technologies ASA · OSL:AZT
ArcticZymes Technologies ASA — Q3 2026 Earnings Presentation
24 slides from ArcticZymes Technologies ASA's earnings presentation, Nov 5, 2026
Slide 1: Strategy Execution Drives Strong and Profitable Growth
November 5th, 2026 Q3 2026 CEO Michael Akoh CFO Børge Sørvoll CCO Paul Blackburn Strategy Execution Drives Strong and Profitable Growth
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking in
Slide 3: Agenda
Agenda 1 Q3 Highlights and Strategy 2 Commercial Update 3 Financial Performance 4 Outlook and summary 5 Q&A
Slide 4: Continued growth in Q3
Q3 2026 · HIGHLIGHTS Continued growth in Q3 FINANCIAL PERFORMANCE MILESTONES BIOMANUFACTURING · +44% TOTAL REVENUE · MNOK SALES REVENUE · MNOK EBITDA · MNOK CDMO sales more than doubled New CDMO adopts M-SAN for in vivo CAR-T 33.0 32.9 3.1 Constant Exchange Rates MOLECULAR TESTING 35.3 MNOK · +24% E
Slide 5: Building a Scalable Enzyme Platform
Building a Scalable Enzyme Platform Strategic pillars accelerating growth and resilience Umbrella Strategy Customer focused market approach Transition from product-oriented enzyme supplier, to a customer centric, application lead/solutions provider Create a wider base – diversification Increase the
Slide 6: Commercial Update Q3 2026
Commercial Update Q3 2026
Slide 7: Q3 2026 Sales Highlights
Q3 2026 Sales Highlights Double-digit growth for a third quarter / +24% at constant currency Total Sales (MNOK) +15% YoY 36 34.1 32.9 MNOK +4.4 MNOK vs Q3 2025 ~7% FX headwind 32.9 31.8 31.9 32 12 Month Average Sales (MNOK) 34 32.7 28.5 31.6 32 +34% 30.3 28 26.8 29.4 29.0 30 28.2 28 27.0 26.1 25.7 2
Slide 8: Regional Performance
Regional Performance Europe leads growth, US recovering as predicted, APAC momentum broadens reach Europe 18.9 MNOK +26% YoY EU CDMOs Contributed most, UK slower US 12.1 MNOK Flat YoY US East recovering, US Central slower APAC Larger distributor orders in India and 1.9 MNOK +40% YoY China; Focus on
Slide 9: Biomanufacturing
Biomanufacturing CDMOs scaling into GMP manufacturing power a breakout quarter Biomanufacturing Sales (MNOK) Biomanufacturing +44% YoY 20 18.1 18.8 18.8 MNOK +18% QoQ 3rd-best quarter ever 18 15.9 Biomanufacturing in Q3: what matters 16 15.2 15.1 GMP sales +227% YoY 7.0 MNOK in Q3 vs 2.1 13.6 M-SAN
Slide 10: Molecular Tools
Molecular Tools A pause after a record run – the underlying trend remains upward Molecular Tools Sales (MNOK) Molecular Tools -8% YoY 18,8 18,8 16,6 14.1 MNOK 9M: +39% YoY Production re-run 16,0 15,4 14,6 14,1 12,3 Molecular Tools in Q3: what matters 10,6 9,7 8,6 4 of 4 Key product groups on track f
Slide 11: 9M 2026 - Growth Sustained
9M 2026 - Growth Sustained Both segments growing / Sales +23% (+33% constant currency) Total Sales Q1–Q3 Revenues (MNOK) 96.6 MNOK 23% growth YoY 2025 +18.1 MNOK vs 9M 2025 +37% +19% +15% 35 32.9 31.8 31.9 28.5 30 26.8 25 23.3 Molecular Tools Biomanufacturing 20 15 46.6 MNOK 50.0 MNOK 10 Q1 Q2 Q3 39
Slide 12: Launched October 2026 | Early-access programme under way
Launched 27 October 2026 | Early-access programme under way
Slide 13: RNA Manufacturing, Explained Simply
RNA Manufacturing, Explained Simply Enzymes are precision tools – ours make RNA therapeutics cheaper and faster 1 Make the RNA 2 Clean up 3 Check quality RiboClean RiboCleave 1 Drug developers make RNA - DNA from production must be Each batch is tested to confirm removed. the RNA is correct. Instruc
Slide 14: Why It Matters
Why It Matters What the RNA enzyme launch delivers FOR OUR CUSTOMERS FOR ARCTICZYMES Lower cost per batch Diversification RiboClean is modelled to cut nuclease cost by more RNA becomes our third growth pillar, alongside Molecular than 80%, using 10× less enzyme. Tools and Viral Vector. Faster answer
Slide 15: Financial Performance
Financial Performance
Slide 16: Profitable growth – currency masks underlying momentum
Profitable growth – currency masks underlying momentum Sales +15% reported, +23% at constant currency Sales & EBITDA Q3 YTD 2026 2025 2026 2025 Sales revenues 32,9 28,5 96,6 78,5 Sales EBITDA 35 Other revenues 0,1 1,2 5,5 5,0 Sum revenues 33,1 29,7 102,1 83,6 30 Cost of materials -2,0 0,1 -4,3 -2,7
Slide 17: Stronger NOK reduces reported sales by MNOK 2.4
USD NOK Stronger NOK reduces reported 12 11,5 sales by MNOK 2.4 11 10,5 NOK strengthened against EUR/USD 10 9,5 9 Norwegian krone strengthened against the USD 8,5 and the Euro in Q3 2026, and compared to Q3 8 2025 2025 2026 Norwegian krone strengthened against USD and EURNOK EURO in 9M 2026 12,5 12
Slide 18: Cost reflect growth investments and temp. items
Cost reflect growth investments and temp. items Commercial execution prioritised Temporary or timing-related Q3 YTD 2026 2025 2026 2025 MNOK 0.7 production re-run cost. Under Sales revenues 32,9 28,5 96,6 78,5 control now Other revenues 0,1 1,2 5,5 5,0 Sum revenues 33,1 29,7 102,1 83,6 Currency head
Slide 19: Cash flow and short-term investments
Cash flow and short-term investments Strong cash position supports future growth Cash and STI position 30 290 Short term investments (STI) Net Cash (MNOK) Changes in Cash and STI (MNOK) 25 270 20 Changes in cash and STI (MNOK) 250 Net Cash (MNOK) 15 230 10 210 5 190 170 0 150 -5 Q1 2025 Q2 2025 Q3 2
Slide 20: Outlook and Summary
Outlook and Summary
Slide 21: Priorities Unchanged | Execution excellence
Priorities Unchanged | Execution excellence Focused execution against the Capital Markets Day priorities OUR AMBITION OUR EXECUTION Core priorities (2026-2028): Sustainable double-digit growth, targeting outperformance of served markets: Scale a high-performance commercial engine Innovation thro
Slide 22: Executing on our five priorities presented at the CMD
Executing on our five priorities presented at the CMD Q3 delivery on strategic objectives 2026–2028 CORE PRIORITY PROOF DELIVERY DETAIL NEXT PROOF POINT Scale a high-performance Repeat orders and broader account 1 commercial engine +15% 9M sales growth | +33% at constant currency penetration Innovat
Slide 23: Summary
Summary A broader and more embedded enzyme platform GROWTH +23% Nine-month sales growth, +33% at CER P R O F I T AB I L I T Y NOK 12.1m Nine-month EBITDA, up from NOK 3.7m a year ago L E V E R AG E +23% / +13% Sales growth vs. operating expense growth, 9M STRENGTH Board has asked management to evalu
Slide 24: Thank you Q & A
A. ArcticZymes Tochnobeceane
ArcticZymes Technologies — Q3 2026 Earnings Presentation on 6ix